Primary mediastinal large B-cell lymphoma : Impact of chemotherapy choice | Zendy

Rehab S. Elhagracy | Zendy; Abdulaziz Hamadah | Zendy; Rasha abd el Tawab | Zendy; Karen Pinto | Zendy; A. Hussain | Zendy; Mohammad Osmani | Zendy; Salem Alshemmari | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Primary mediastinal large B-cell lymphoma : Impact of chemotherapy choice

Author(s) -

Rehab S. Elhagracy,

Abdulaziz Hamadah,

Rasha abd el Tawab,

Karen Pinto,

A. Hussain,

Mohammad Osmani,

Salem Alshemmari

Publication year - 2021

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2021.05.002

Subject(s) - epoch (astronomy) , vincristine , medicine , rituximab , chop , prednisone , single center , etoposide , cyclophosphamide , chemotherapy , lymphoma , surgery , oncology , clinical endpoint , clinical trial , stars , physics , astronomy

Data generated from retrospective studies on primary mediastinal B-cell lymphoma (PMBCL) outcome are valuable as no prospective phase 3 trials have been conducted in this rare type of lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research